ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Drug Trials for Hearing Loss, Tinnitus Therapies Show Promise

by David Bronstein • June 8, 2015

  • Tweet
  • Email
Print-Friendly Version

Dr. Meyer said he has been involved in researching tinnitus-targeted drug therapy since 2003, when he first launched Auris Medical. During that time, he noted, he has learned that selectivity is one of the keys to successful drug development. In the case of tinnitus, “you not only have to target the right type or etiology, where you fully understand the biology; you also have to be very specific regarding the type of patient you’re treating. For us, our clinical data suggest that patients in the early stages of the disorder—up to three months out, possibly more—will respond best to our approach.”

You Might Also Like

No related posts.

Explore This Issue
June 2015

Dr. Meyer said he is optimistic that a phase 3 trial of acute tinnitus launched in the United States in February 2014, known as TACTT2, will replicate the positive findings of previous trials.

Another Mechanism, Another Hearing Disorder

Auris Medical also has several clinical trials in the works in the United States and Europe that focus on sudden and surgery-induced hearing loss. The drug being evaluated, AM-111, is a stress kinase inhibitor peptide known as D-JNKI-1 that is formulated in a biocompatible and biodegradable gel. By acting on that kinase, AM-111 prevents apoptosis in hair cells and also attenuates the damaging effects of cellular inflammation following acute inner ear injury (Hear Res. 2007;226:168-177).

In a phase 2 clinical trial of AM-111, patients with severe to profound sensorineural hearing loss (PTA thresholds > 60dB) who were treated with 0.4 mg/mL of the drug showed an absolute improvement in hearing loss to day seven of the study (29.9 dB vs. 17.9 dB for place-treated patients; P=0.017) (Otol Neurotol. 2014;35:1317-1326). The drug was well tolerated, with no negative impact on hearing, balance, or tinnitus.

Dr. Meyer said he is excited by the prospect of seeing the first drugs specifically developed for inner ear therapy moving towards broad clinical use. “If all goes well, there will be FDA drugs approved for intratympanic treatments in a few years from now,” he said. “That could have quite an impact on the field of otology.”

Hinrich Staecker, MD, PhD, a professor of otolaryngology and head and neck surgery at the University of Kansas Medical Center in Kansas City, has participated in all three clinical trials involving AM-101. Although “we’re not long enough out” on the phase 3 study, “based on what we’ve seen with prior patients, the prospects for this drug therapy are very promising,” he said.

Pages: 1 2 3 4 | Single Page

Filed Under: Home Slider, Otology/Neurotology, Practice Focus, Special Report Tagged With: drugs, hearing loss, medication, tinnitusIssue: June 2015

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Complications for When Physicians Change a Maiden Name
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Otolaryngologists Elected to AMA Board of Trustees
    • FDA Approves First Treatment for Eosinophilic Esophagitis
    • Clinical Best Practices: Otolaryngologists Tackle Questions
    • Otolaryngologist Shares Experience with Image Manipulation in Research and How to Prevent It
    • Methodology to Study Care Barriers for Head and Neck Cancer Patients in Low- and Middle-Income Countries Yields Insights

Polls

Do you think most image manipulation in studies is done accidentally or on purpose?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2022 The Triological Society. All Rights Reserved.
ISSN 1559-4939